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Immunoglobulin E and its interactions with receptors FcRI
and CD23 play a central role in allergic disease. Omalizumab, a
clinically approved therapeutic antibody, inhibits the interac-
tion between IgE and FcRI, preventing mast cell and basophil
activation, and blocks IgE binding to CD23 on B cells and anti-
gen-presenting cells.We solved the crystal structure of the com-
plex between an omalizumab-derived Fab and IgE-Fc, with one
Fab bound to each C3 domain. Free IgE-Fc adopts an acutely
bent structure, but in the complex it is only partially bent, with
large-scale conformational changes in the C3 domains that
inhibit the interaction with FcRI. CD23 binding is inhibited
sterically due to overlapping binding sites on each C3 domain.
Studies of omalizumab Fab binding in solution demonstrate the
allosteric basis for FcRI inhibition and, togetherwith the struc-
ture, reveal how omalizumab may accelerate dissociation of
receptor-bound IgE fromFcRI, exploiting the intrinsic flexibil-
ity and allosteric potential of IgE.
Immunoglobulin E (IgE) antibodies play a crucial role in
allergic disease, binding to allergens through their Fab arms and
expressing their effector functions by binding to receptors for
the Fc region (1). The two principal IgE receptors are FcRI and
CD23/FcRII, commonly referred to as the high- and low-affin-
ity receptors, respectively. On mast cells and basophils, IgE
binds to FcRI so tightly (KD 1010 M) that such cells are
sensitized with pre-bound IgE, requiring only the presence of
an allergen to cross-link IgE/FcRI complexes and elicit an
immediate reaction. CD23 is a homotrimer, and thus the intrin-
sically lower affinity of each IgE-binding C-type lectin-like
“head” domain (KD 107 M) can be enhanced by an avidity
effect when binding to aggregated IgE in immune complexes,
nearly matching that of FcRI for IgE (2). CD23 expressed on B
cells is involved in IgE regulation, and expression on airway and
gut epithelial cells mediates transcytosis of IgE/allergen com-
plexes (1, 2). FcRI andCD23 are also both expressed on a range
of antigen-presenting cells. Thus IgE-receptor interactions are
involved in multiple aspects of the allergic response, and IgE is
a long-standing target for therapeutic intervention (3).
The Fc region of IgE comprises a disulfide-linked dimer of
three domains: C2, C3, and C4. Early FRET studies of a chi-
meric IgE (4, 5), and X-ray solution scattering studies of IgE-Fc
(6), indicated a compact, bent structure, and the crystal struc-
ture of IgE-Fc later revealed an acutely and asymmetrically bent
conformation, with the (C2)2 domain pair folded back onto
the C3 and C4 domains (7). The bend, defined as the angle
between the local 2-fold axis of the (C2)2 domain pair and that
of Fc3–4 (the region comprising only the C3 and C4
domains), was found to become even more acute in the crystal
structure of IgE-Fc bound to sFcRI, the soluble extracellular
domains of the IgE-binding -chain of the receptor (8). FRET
studies with N- and C-terminally labeled IgE-Fc confirmed this
enhanced bend upon sFcRI binding (9).
The FcRI-binding site spans both C3 domains in the C2-
proximal region (8, 10), although the C2 domain is not directly
involved; the engagement of both chains accounts for the 1:1
binding stoichiometry. In contrast, two CD23 molecules bind
to IgE-Fc, one in each chain, and at the other C4-proximal end
of the C3 domain (11–14). CD23 binding also causes a confor-
mational change in IgE-Fc (14), but not one that significantly
affects the bend (9).However, the relatively “closed” disposition
of the C3 domains in the complex with the soluble head
domain ofCD23 (sCD23), comparedwith free IgE-Fc, is incom-
patible with the more “open” arrangement of these domains
that is required for FcRI binding. This partly explains the
mutual exclusion of FcRI and CD23 binding (11, 12), although
other factors such as local conformational changes and modi-
fications of conformational dynamics (15) also likely contribute
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to the allosteric communication between the two receptor-
binding sites (2).
A more extreme degree of flexibility in IgE-Fc was recently
discovered through studies of a complex with an anti-IgE-Fc
Fab, termed aFab (16). Two aFabmolecules bind to IgE-Fc in
a symmetrical manner, one on each C3 domain, trapping a
fully extended conformation in which the local 2-fold axes of
the (C2)2 domains and Fc3–4 region are virtually coincident.
Analysis of the complex formation in solution, together with
molecular dynamics simulations of free IgE-Fc, suggests that
the (C2)2 domain pair could “flip” over from one side of the
Fc3–4 region to the other (16). The IgE-Fc conformation sta-
bilized by this anti-IgE antibody is incompatible with FcRI
binding, explaining its inhibitory activity (16).
Omalizumab is an anti-IgEmonoclonal IgG1 antibody that is
approved for therapeutic use (Xolair, Novartis) (17). It binds
to free IgE and inhibits both FcRI and CD23 binding. The site
of binding had been mapped to the C3 domain by peptide
inhibition andmolecular modeling and was recently confirmed
by a crystal structure (18–20). Recently, an inhibitor was dis-
covered that actively disrupted preformed IgE/FcRI com-
plexes: a Designed Ankyrin Repeat Protein (DARPin) was
found to bind to the C3 domain of receptor-bound IgE and
accelerate its dissociation from FcRI (21). The crystal struc-
ture of the 2:1 complex of thisDARPin (DARPin E2_79)with an
Fc3–4 molecule constrained by an engineered disulfide bond
(G335C), which artificially locks the C3 domains into a closed
conformation, revealed the nature and location of the binding
site but left its mechanism of action unclear. It was subse-
quently reported that omalizumab could also facilitate dissoci-
ation of FcRI-bound IgE, although only at very high concen-
trations that were substantially greater than those utilized
therapeutically (22, 23). Omalizumab binding to FRET-labeled
IgE-Fc indicated a slight degree of unbending (9) and the poten-
tial for allosteric rather than direct inhibition of FcRI binding.
The recent crystal structure of an omalizumab Fab complex is
with the same Fc3–4 molecule present in the DARPin com-
plex (20); this constrained Fc3–4 construct lacks the C2
domains and thus cannot report on unbending or other confor-
mational changes.
We report here the crystal structure of the complex between
IgE-Fc and a Fab derived from omalizumab. The structure of
the complex reveals substantial conformational changes in IgE-
Fc, revealing the mechanism of action of omalizumab, both for
receptor inhibition and accelerated dissociation of IgE from
FcRI. Solution studies demonstrate that these mechanisms
exploit the intrinsic flexibility of IgE.
Results
Despite extensive efforts, crystallization trials for IgE-Fc in
complex with the omalizumab Fab resulted in selective crystal-
lization of the Fab fragment only. Others have reported a sim-
ilar failure to crystallize the complex with IgE-Fc (24). The
recently reported structure for the omalizumab Fab complex
(20) is with an Fc3–4 molecule that contains a G335C muta-
tion; this mutation artificially locks the C3 domains into a
closed conformation. We designed a Fab, derived from omali-
zumab, with three point mutations, two in the VL domain
framework region (S81R and Q83R) and one in the C domain
(L158P) (supplemental Fig. S1), with the purpose of disrupting
favorable crystal contacts observed in the omalizumab Fab
crystal structure. We term this omalizumab-derived Fab
FabXol3.
Overall structure of the FabXol3/IgE-Fc complex
Wedetermined the crystal structure of the complex between
IgE-Fc and FabXol3 to 3.7 Å resolution (Fig. 1 and supplemen-
tal Movie S1). Two FabXol3 molecules (Fab1 and Fab2) bind to
an asymmetric, partially bent IgE-Fc molecule, and the Fab
engages one edge of the exposed face of each C3 domain (Fig.
1). Fab1 engages the C3 domain of IgE-Fc chain B, whereas
Figure 1. Overall structure of IgE-Fc in complex with FabXol3. A, FabXol3
binds to IgE-Fc with 2:1 stoichiometry. Fab1 (green) engages IgE-Fc chain B
(pink) exclusively through the C3 domain. Fab2 (blue) interacts with IgE-Fc
chain A (yellow) through the C3 domain and forms a minor interaction with
the C2 domain from IgE-Fc chain B (pink). B, two Fabs form a pseudo-sym-
metric complex about the 2-fold axis of the Fc3–4 region. For clarity, the C2
domains are not shown. C, IgE-Fc is asymmetrically bent in the FabXol3 com-
plex. The C2 domain from chain B (pink) contacts Fab2 (blue).
Allosteric mechanism of action of omalizumab
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Fab2 engages the C3 domain of IgE-Fc chain A. Because of the
partially bent conformation of IgE-Fc in the complex, the light
chain of Fab2 also forms a minor interaction with the C2
domain from IgE-Fc chain B (see supplemental data for details
of this interaction). The overall structure of IgE-Fc in complex
with FabXol3 is compared with that of the constrained Fc3–4
molecule in complex with the omalizumab Fab (20) in Fig. 2.
The FabXol3/IgE-Fc complex not only reveals the effect of
omalizumab binding on the position of the (C2)2 domain pair
(Fig. 2A), which is absent in the Fc3–4 molecule (Fig. 2B), but
also shows that the C3 domains adopt a markedly open con-
formation (Fig. 2, C and E), one that cannot be adopted by the
disulfide-bondedC3 domains in the Fc3–4 complex (Fig. 2,D
and F). The bending of the (C2)2 domain pair and the opening
of the C3 domains are described in detail below.
Interface between IgE-Fc and FabXol3
Each FabXol3molecule engages one edge of the exposed face
of theC3 domain (C, C, F, andG strands and base of the FcRI
receptor-binding FG loop). The interface with IgE-Fc is similar
to that reported for the constrained Fc3–4molecule (20). Both
the heavy and light chain of FabXol3 are involved, the former
contributing60% to an interface area of715 Å2 (Figs. 1 and
3A and supplemental Movie S1).
The FabXol3 heavy chain contacts, which differ slightly
between the two interfaces, may be summarized as follows:
Gly-32 and Tyr-33 (CDRH1) form van der Waals interactions
withAla-377 and Ser-378 (C3), whereasTyr-54 (CDRH2) con-
tacts Gly-379–Pro-381 (C3). The CDRH3 residues contribute
the largest contact area and undergo a significant conforma-
tional change upon complex formation, when compared with
unbound Fab structures (19, 20, 24). CDRH3 residues Ser-100,
His-101, Tyr-102, and Trp-106 all form van der Waals interac-
tions with C3 domain residues that include Ser-375–Gly-379,
Gln-417, and Arg-419 (C3). However, the most striking fea-
ture of this part of the interface is the interaction with Phe-103
(CDRH3). Phe-103 is mostly buried in a pocket created by Thr-
373, the Trp-374 main chain, Ser-375, Gln-417, and Arg-419
(C3), and it forms a cation/-stacking interaction with Arg-
419 (Fig. 3A).
Arg-419 also plays a key role in the interaction with the
FabXol3 light chain (Fig. 3A). Arg-419 is within hydrogen-
bonding distance of the Tyr-31 (CDRL1) and Asp-32 (CDRL1)
main chain carbonyl oxygen atoms, in addition to contacting
the Asp-32, Asp-34, and Tyr-36 side chains (forming a hydro-
gen bond with the Tyr-36 hydroxyl group). Asp-32 also forms
van derWaals interactionswithThr-373 andThr-421 (C3). By
contrast, only two CDRL2 residues contribute to the interface,
Tyr-53 (CDRL2) contacts Gln-417 (C3), and both Tyr-53
and Tyr-57 form van der Waals interactions with Met-430
(C3); Tyr-57 also forms a hydrogen bond with the Met-430
Figure 2. Comparison of the FabXol3/IgE-Fc and omalizumab Fab/Fc3–4 complexes. A, side view of IgE-Fc (yellow and pink) in the FabXol3 (green and
blue) complex, showing theasymmetricbend in IgE-Fc.B, sideviewof theconstrainedFc3–4molecule (pale yellowandpink) in theomalizumabFab (greenand
blue) complex (20). C, front view of IgE-Fc in the FabXol3 complex (90° clockwise rotation from the view shown in A). For clarity, the (C2)2 domain pair is not
shown.D, front viewof theconstrainedFc3–4molecule in theomalizumabFabcomplex (90° clockwise rotation fromtheviewshown inB).E, topviewof IgE-Fc
in the FabXol3 complex (90° rotation toward the reader from theviewshown inC). For clarity, the (C2)2 domainpair is not shown. F, topviewof the constrained
Fc3–4molecule in theomalizumabFabcomplex (90° rotation toward the reader fromtheviewshown inD). Thepositionof theengineereddisulfidebond that
locks the C3 domains into a closed conformation is colored red.
Allosteric mechanism of action of omalizumab
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backbone. As for the heavy chain interaction, there are slight
differences in the light chain contacts for Fab1 and Fab2.
Comparison of the FabXol3 interface with other anti-IgE
complexes
The binding sites on the C3 domain for FabXol3 and the
recently describedDARPin E2_79 (21) overlap (Fig. 3B) and are
of similar size at 715 and 753 Å2, respectively. The C3
domain residues shared between the two interfaces include Ser-
375–Gly-379, Gln-417, Arg-419, Arg-427, and Met-430, but
although FabXol3 forms more intimate contacts with the
receptor-binding C3 FG loop, the DARPin E2_79 interface
extends in the opposite direction to include the C3–4 domain
linker.
The overlapping binding sites of FabXol3 andDARPin E2_79
differ markedly from the interface recently described for the
anti-IgE-Fc aFab, which captured IgE-Fc in a fully extended
conformation (Fig. 4) (16). Not only is the aFab interface area
approximately double that of FabXol3 and DARPin E2_79, at
1400 Å2, but aFab engages IgE-Fc at a site centered on Arg-
393 in C3, and it also contacts residues in the C2 domain and
the C2-C3 linker (16). The crystal structure of another anti-
IgE antibody Fab, MEDI4212, in a 2:1 complex with Fc3–4
reveals yet another site for antibody engagementwithin theC3
domain, this one involving theN-linked oligosaccharidemoiety
at Asn-394 (25).
IgE-Fc adopts a partially bent conformationwhen bound to
FabXol3
IgE-Fc is predominantly bent in solution (4–6, 9, 26–28),
and the crystal structure for free IgE-Fc revealed an acutely bent
(62°) asymmetric conformation, in which the (C2)2 domain
pair folded back onto theC3 andC4 domains (Fig. 4,A andB),
the C2 domain of one chain (chain B) contacting the C4
domain of the other (chain A) (7, 8). IgE-Fc becomes evenmore
acutely bent (54°) upon FcRI engagement (8, 9), and the asso-
ciated conformational changes involve rotation of the C3
domain of chain A together with the (C2)2 domain pair, as a
rigid unit, away from the C3 domain of chain B (8).
In contrast to the aFab complex, in which IgE-Fc adopts a
fully extended, linear conformation (16), IgE-Fc adopts a par-
tially bent conformation in the FabXol3 complex (Figs. 1C and
4, C–F, and Movies S1 and S2). The site to which Fab1 binds is
exposed in free, acutely bent IgE-Fc, but further unbending of
IgE-Fc, to just over 90°, is required to render the site occupied
by Fab2 accessible. This unbending of IgE-Fc in the FabXol3
complex is associated with opening of both C3 domains to
create an almost symmetrical Fc3–4 region (Figs. 1B and 4, C
and D).
In a recent molecular dynamics simulation exploring
unbending of IgE-Fc to an extended structure, it was found that
although the acutely bent conformation observed in the crystal
structure of free IgE-Fc occupied the lowest energy basin,
another distinct and well defined energy basin, corresponding
to partially bent IgE-Fc conformations, was observed (16). The
partially bent conformation adopted by IgE-Fc in the FabXol3/
IgE-Fc complex occupies this particular energy basin (supple-
mental Fig. S2).
To test whether we could observe these conformational
changes in solution, we performed intramolecular FRET mea-
surements with IgE-Fc labeled with donor and acceptor fluoro-
Figure 3. A, interface between FabXol3 and IgE-Fc. The interface between FabXol3 Fab2 (heavy and light chains colored in green and yellow, respectively) and
the C3 domain from IgE-Fc (pink) is shown. FabXol3 and C3 domain residue labels are colored blue and black, respectively. The interface includes hydrogen
bonds andvanderWaals interactions. Anotable featureof the interface is a cation/ interactionbetweenArg-419 (C3domain) andPhe-103 (FabXol3CDRH3).
The Phe-103 side chain ismostly buried in apocket createdby Thr-373, Trp-374, Ser-375, Gln-417, andArg-419 (C3domain).B, FabXol3 andDARPin E2_79 (21)
bind to anoverlapping interfaceon theC3domain. IgE-Fc residues,whichonly formpart of the FabXol3 interface, are coloredorange, and those that only form
part of the DARPin E2_79 interface, which includes part of the C3-C4 linker, are colored in blue. IgE-Fc residues colored in pink, which include Arg-419 and
Met-430, are common to both FabXol3 and DARPin E2_79 interfaces.
Allosteric mechanism of action of omalizumab
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Figure4. Conformational flexibility in IgE-Fc.A, side viewof free IgE-Fc (8) showing its acute asymmetric bend.B, front viewof free IgE-Fc (90° anti-clockwise
rotation from the view shown in A). C, side view of IgE-Fc from the FabXol3 complex, revealing a partially bent conformation. D, front view of IgE-Fc in the
FabXol3 complex (90° anti-clockwise rotation from theview shown inC). E, side viewof fully extended IgE-Fc capturedbyananti-IgE-Fc Fab (aFab) (16). F, front
view of extended IgE-Fc (90° anti-clockwise rotation from the view shown in E).
Allosteric mechanism of action of omalizumab
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phores in the C2 domains and at the C termini, respectively.
We have previously shown that binding of aFab results in a
nearly fully extended IgE-Fc structure (16); data here indicate a
90% reduction of the FRET signal (Emax 91%, IC501M)
when two molecules of aFab are bound to IgE-Fc (Fig. 5). In
contrast, FabXol3, despite its higher affinity, shows only about
50% reduction of the intramolecular FRET signal under satu-
rating conditions (Emax  52%, IC50  7 nM). These experi-
ments support the hypothesis that binding of FabXol3 induces
large-scale conformational changes in IgE-Fc, consistent with a
partially bent conformation.
C3 domains adopt amarkedly open conformation in the
FabXol3/IgE-Fc complex
In crystal structures of IgE-Fc and the Fc3–4 sub-fragment,
the C3 domains adopt a range of different orientations (7, 8,
10, 11, 13, 14, 16, 25, 29), a property associated with allosteric
regulation of IgE binding to its two principal receptors, FcRI
and CD23 (8, 11–14). Both the distance between the C3
domains and their positions with respect to the C4 domains
have been used to describe the variety of conformations
observed for the Fc3–4 region (29) (a full description for
these measurements is provided in supplemental data). In the
FabXol3/IgE-Fc complex, the C3 domains are positioned fur-
ther away from one another than in any other crystal structure
containing IgE-Fc or Fc3–4 and thus adopt the most open
conformation observed thus far (Figs. 1B and 4, C and D,
and supplemental Movie S2); this conformation is significantly
more open than the conformation for FcRI-bound IgE-Fc
(supplemental Fig. S3).
Effect of FabXol3 on FcRI and CD23 receptor binding
Omalizumab inhibits not only the interaction between
IgE-Fc and FcRI, but also the interaction between IgE-Fc and
CD23 (30). Consistent with the latter, superposition on the C3
domains from the FabXol3/IgE-Fc structure, and the previously
reported structure of CD23 in complex with an Fc3–4 mole-
cule (11), reveals steric clashes between FabXol3 and CD23 at
both sites of CD23 engagement on the C3 domain. Further-
more, C3 domain residues Arg-376, Ser-378, and Lys-380 are
involved in both FabXol3 and CD23 binding (Fig. 6, A and B)
(11, 13, 14, 31). Thus, omalizumab inhibits CD23 binding by
orthosteric blocking.
In contrast to CD23 binding to IgE, FcRI binds across both
C3 domains. However, in the FabXol3/IgE-Fc complex, the
C3 domains adopt a conformation that is more open than in
FcRI-bound IgE-Fc, which precludes simultaneous engage-
ment of both chains (Fig. 6, C–E). Moreover, superposition of
the FabXol3/IgE-Fc and sFcRI/IgE-Fc (8) complexes reveals
potential steric clashes; for example, FabXol3 would clash with
the (C2)2 domain pair from the acutely bent conformation
found in FcRI-bound IgE-Fc.
Also in contrast to CD23, the binding sites for omalizumab
and FcRI do not actually overlap, although FabXol3 CDRL1
residues are positioned immediately adjacent to the FcRI-
binding C3 domain FG loop. This loop, in chain B, contributes
to a hydrophobic “proline sandwich” interaction, in which Pro-
426 in C3 packs between two tryptophan residues of FcRI
(Fig. 6E). Asp-32 (CDRL1) contacts Thr-421; Gly-33 (CDRL1)
contacts Pro-426, Arg-427, and Ala-428; and Asp-34 (CDRL1)
contacts Arg-427 and Ala-428. These interactions alter the
position of theC3 domain FG loop andwould further compro-
mise the binding of IgE to FcRI.
Thus, omalizumab binding stabilizes a conformation of IgE-
Fc, which is incompatible with FcRI binding.
Interaction of FabXol3 with IgE-Fc in solution
Recently, binding of omalizumab to FcRI-bound Fc3–4
has been reported (22), although it is difficult to see how omali-
zumab might be able to engage FcRI-bound IgE based on the
static crystal structures of IgE-Fc in complex with sFcRI (8)
and FabXol3. We therefore studied the solution state binding
of FabXol3 to IgE-Fc, and we characterized the interaction
between FabXol3 and the IgE-Fc/FcRI complex. Our results
provide insights into the mechanism of action of omalizumab.
We characterized the IgE-Fc/FabXol3 interaction in two dif-
ferent ways, either by directly immobilizing FabXol3, FabXol
(omalizumab Fab), or intact omalizumab on an SPR5 sensor
surface and binding IgE-Fc, or by binding FabXol3 to His-
tagged captured IgE-Fc. The binding characteristics of IgE-Fc
to FabXol3, FabXol, and omalizumab were compared (Fig. 7,
A–C). Not surprisingly, in competition binding experiments,
all three molecules competed for the same binding sites and
showed broadly similar binding affinities; the FabXol3 con-
struct demonstrates slightly higher affinity compared with
FabXol and intact omalizumab (Fig. 7, A–C). Consistent with
the crystal structure, two FabXol3molecules bind to IgE-Fc; the
binding is clearly biphasic with a high-affinity (1 nM) interac-
tion observed at low ligand concentrations and a second
(weaker) binding site (30 nM) observed at higher concentra-
tions (Fig. 7D). It might be speculated that the higher affinity
interaction corresponds to the binding of Fab1, which would
have unimpeded access to a bent IgE-Fc molecule, whereas the
lower affinity and slower on-rate corresponds to Fab2, but we
cannot be definitive about this.
5 The abbreviations used are: SPR, surface plasmon resonance; TR-FRET, time
resolved-FRET.
Figure 5. Effect of anti-IgE Fabs on IgE-Fc conformation measured by
FRET. The FRET ratio (E520/E485) was measured in the presence of different
concentrations of anti-IgE Fabs, either FabXol3 (magenta), aFab (green), or
control Fab (blue). aFab has previously been shown to fully unbend IgE-Fc
(16); the control Fab binds to the C2 domain of IgE-Fc and does not cause
unbending of the molecule.
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A sandwich-style SPR experiment allowed the two FabXol3-
binding sites to be observed and characterized separately.Using
this approach, FabXol3 was covalently immobilized on a sensor
surface, and IgE-Fc was flowed over this surface. At low con-
centrations, under these conditions, the high-affinity site dom-
inates the interaction, and the binding curves can be described
by monophasic interaction kinetics (KD1 nM, kon1.2 106
M1 s1, and koff  8  104 s1). This 1:1 FabXol3/IgE-Fc
complex, captured on the SPR biosensor surface, could then be
used to measure the binding of the second FabXol3 molecule,
the binding of which is significantly weaker (KD30 nM, kon
2 105M1 s1, and koff 6 103 s1) than the first (Fig. 7E).
Again, the slower association rate constant measured for the
second (weaker) interaction would be consistent with the Fab
binding to the less accessible of the two binding sites, i.e. the
Fab2 site in the crystal structure.
In characterizing the binding of the two different FabXol3
molecules, we observed that binding of the second FabXol3
molecule destabilized the 1:1 FabXol3/IgE-Fc complex; this
destabilization of a pre-formed complex is the same phenome-
non of accelerated dissociation that has been seen in IgE in
relation to FcRI binding (21, 22). We also saw that the
FabXol3-mediated accelerated dissociation of the FabXol3/
IgE-Fc complex was highly temperature-dependent, with
essentially no FabXol3-mediated accelerated dissociation
occurring at 5 °C but marked accelerated dissociation occur-
ring at 35 °C (Fig. 8). Because of their physically distal binding
sites and the strong temperature dependence of the phenome-
non, the ability of the second FabXol3 molecule to mediate
accelerated dissociation of the 1:1 FabXol3/IgE-Fc complex
must be an allosterically mediated process.
Competition between the FabXol3- and FcRI-binding sites
and the formation of a FabXol3/IgE-Fc/FcRI complex
We next investigated the capacity of FabXol3 to affect the
interaction between IgE-Fc and FcRI. In solution competi-
Figure6.Disruptionof the interactionbetween IgE-FcandCD23andbetween IgE-FcandFcRI.A,C3domain residues that are common tobothFabXol3
and CD23 interfaces are colored pink. B, superposition of the C3 domains from the FabXol3/IgE-Fc complex (light pink) and the previously reported crystal
structure of CD23 in complexwith Fc3–4 (11) (light green) reveals clashes betweenCD23 (green) and FabXol3 (dark pink). The CD23/Fc3–4 complex structure
(11) is with an IgE-Fc construct (Fc3–4) that lacks the (C2)2 domain pair. For clarity, the C4 domains are not shown. C, in the FabXol3 complex, the C3
domains adopt the most open conformation reported thus far for IgE-Fc, which precludes engagement with FcRI. The structure of IgE-Fc in complex with
sFcRI (8) is colored yellow, and the two sub-sites of receptor engagement are indicated. The structure of FabXol3 in complex with IgE-Fc (blue) was
superposedon theC4domains.D,positionsof Pro-365andHis-424at sub-site 1 are indicated tohighlight thedifferentpositions adoptedby theC3domains.
E, substantial displacement of Pro-426 in the FabXol3 complex prevents engagement of the proline sandwich at sub-site 2.
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tion binding experiments, increasing concentrations of FabXol3
inhibited binding of IgE-Fc to FcRI (Fig. 9A). Mechanisti-
cally, FabXol3 affects both the number of available binding sites
(Bmax) and the apparentKD value of the IgE-Fc/FcRI interac-
tion. Reduction in Bmax values is indicative of an allosteric
inhibitory process, and a decrease in the apparent affinity of the
interaction is most commonly associated with direct competi-
tion for a shared binding site (i.e. orthosteric inhibition) but can
also be seen for some allosteric inhibitors (32). Although we
cannot rule out an orthosteric contribution, considering the
lack of overlap between the binding sites observed in the crystal
structures, it is likely that FabXol3 inhibits IgE-Fc binding to
FcRI using primarily allosteric mechanisms.
Competition between the omalizumab- and FcRI-binding
sites has been described inmany publications but was generally
interpreted as direct competition between binding sites that
were presumed to be identical, or at least overlapping. This
interpretation was often used to explain why omalizumab can-
not bind to IgE-FcRI complexes on cells. We observed, how-
ever, that FabXol3 can indeed bind, and with high affinity, to
IgE-Fc that is pre-bound to FcRI to form a trimolecular com-
plex (Fig. 9B, inset). The data indicate that although the binding
of IgE-Fc to FcRI did not significantly change the affinity of
FabXol3 for IgE-Fc, it didmarkedly change the number of avail-
able binding sites for FabXol3 in the population of FcRI-
bound IgE-Fc molecules. We compared the KD and Bmax bind-
ing values for an IgE-Fc molecule captured by an anti-His tag
antibody with one captured by sFcRI, and we found that
FcRI-bound IgE-Fc had less than 10% of the FabXol3-bind-
ing sites compared with the His tag captured IgE-Fc, which, as
expected, showed binding levels consistent with 2:1 stoichiom-
etry (Fig. 9B). Therefore, it is not that omalizumab does not
bind to mast cell-bound IgE because the FcRI and omali-
zumab-binding sites overlap, or because of steric clashes
between two ligands bound to adjacent sites (20). Instead
FcRI acts on IgE-Fc allosterically, changing a dynamic equi-
librium of different IgE-Fc conformations, resulting in a sub-
stantially reduced number of omalizumab-binding sites in a
population of FcRI-bound IgE-Fc molecules.
Mechanism of FabXol3-mediated accelerated dissociation of
the IgE-Fc/FcRI complex
Kim et al. (21) reported that DARPin E2_79 could accelerate
the disassembly of pre-formed complexes of IgE/FcRI. Follow-
ing up on this observation, Eggel et al. (22) later showed that
omalizumab at high concentrations could also promote disso-
Figure 7. Interaction studies of FabXol3with IgE-Fc.Direct bindingwasmeasured for IgE-Fc to immobilized FabXol3 (A), FabXol (B), and intact omalizumab
(C). Fabs or intact antibodies were covalently immobilized at low density using an amine coupling kit (GE Healthcare); IgE-Fcwas flowed over these surfaces at
a variety of concentrations, using a 2-fold dilution series with a highest concentration of 100 nM. D, binding of FabXol3 to IgE-Fc captured via a C-terminal His
tag; FabXol3 was flowed over IgE-Fc in a 2-fold dilution series with a highest concentration of 100 nM. E, binding of the second FabXol3-binding site was
characterized using an SPR sandwich binding experiment. IgE-Fc was captured on a FabXol3 surface, and then a second FabXol3 molecule was added to the
IgE-Fc/FabXol3 complex in a 2-fold dilution series starting at 1000 nM. For all binding experiments, all concentrations were run in duplicate.
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ciation of IgE from FcRI. We have found that when FabXol3
binds to the IgE-Fc/sFcRI complex, it accelerates the disso-
ciation of IgE-Fc from sFcRI (Fig. 9C) and, furthermore, that
FabXol3 does this more efficiently than FabXol, and much
more efficiently than intact omalizumab (Fig. 9D). One Fab
engages the IgE-Fc/sFcRI complex but does not accelerate
the dissociation of IgE-Fc from sFcRI. Strikingly, it appears
that accelerated dissociation occurs only after occupancy of the
second binding site (i.e. the low-affinity site). The (FabXol3)2/
IgE-Fc/sFcRI tetramolecular complex must alter the energy
landscape of IgE-Fc in such a way as to markedly reduce the
energy barrier for IgE-Fc/sFcRI dissociation, resulting in a
rapid dissociation of this otherwise very stable complex.
Discussion
We report the structure, at 3.7 Å resolution, of the complex
between IgE-Fc and a Fab fragment derived from the therapeu-
tic anti-IgE antibody omalizumab; we call this Fab fragment,
which contains three point mutations in framework regions
distal to the antigen-binding site, FabXol3. The structure
reveals two FabXol3 molecules in complex with IgE-Fc, one
bound to each of the two C3 domains, and provides an expla-
nation for the ability of omalizumab to inhibit the binding of
IgE to both FcRI and CD23. IgE-Fc is also found to adopt a
partially bent conformation in the FabXol3 complex, consistent
with intramolecular FRET measurements in solution.
IgE-Fc is predominantly bent in solution (4–6, 9, 26–28),
and in the crystal structure of free IgE-Fc, the (C2)2 domain
pair is folded back against the C3 and C4 domains (7, 8).
Recently, our understanding of the conformational flexibility of
IgE-Fc was profoundly enhanced when we solved the structure
of a fully extended conformation, captured in a complexwith an
anti-IgE-Fc Fab (aFab) (16). Amolecular dynamics simulation,
exploring IgE-Fc unbending from the acutely bent to the
extended conformation, revealed energy basins corresponding
to partially bent conformations. The FabXol3/IgE-Fc complex
reported here, in which the bend between the (C2)2 domain
pair and the Fc3–4 domains is90°, corresponds to a distinct
energy basin in this simulation (16) (supplemental Fig. S2) and
is consistentwith our intramolecular FRETmeasurements (Fig.
5). Intriguingly, the location of the FabXol3-binding site would
not preclude further unbending to the fully extended confor-
mation (supplemental Movie S3), and it is therefore possible
that IgE-Fc can undergo further substantial changes in confor-
mation even when in complex with omalizumab.
In addition to the bending of the (C2)2 domain pair relative
to the C3 and C4 domains, the various IgE-Fc, Fc3–4, and
receptor complex structures have demonstrated that the C3
domains can adopt a range of relative orientations, from closed
to open (7, 8, 10, 11, 13, 14, 16, 25, 29). Opening and closing of
the C3 domains contributes to the allosteric regulation of
receptor binding in IgE-Fc (11, 12); in the CD23 complex they
are relatively closed (11, 13, 14), and in the FcRI complex they
are more open (8, 10). Comparison of the structures of the
CD23/Fc3–4 and FabXol3/IgE-Fc complexes shows that the
CD23 and omalizumab sites overlap, and competition binding
experiments indicate that inhibition of IgE binding to CD23 by
omalizumab is straightforwardly orthosteric.
However, inhibition of FcRI binding is mechanistically dif-
ferent. In the FabXol3 complex, the C3 domains adopt a more
Figure 8. Temperature dependence of the accelerated dissociation of the IgE-Fc/FabXol3 complex, mediated by the binding of the second FabXol3
molecule. Binding of the second FabXol3-binding sitewas characterized using SPR sandwich binding experiments at 5, 15, 25, and 35 °C (A–D). IgE-Fcwas first
captured on a FabXol3 surface and then a second FabXol3molecule was added to the IgE-Fc/FabXol3 complex, in a 2-fold dilution series starting at 1.6M. At
low temperature, almost no FabXol3-mediated accelerated dissociation of the IgE-Fc/FabXol3 complex occurs, whereas the effect is markedly increased at
higher temperatures.
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open conformation than seen in any previous structure, so
much so that the two sub-sites of interaction between IgE-Fc
and FcRI, one involving each C3 domain, cannot engage
simultaneously. In addition to large scale domainmotions, local
conformational changes induced by FabXol3 binding, such as
those in the FcRI-binding FG loop, may also contribute to this
inhibition. Although there is a possibility of steric clashes if
FabXol3 and FcRI bind simultaneously to IgE-Fc, the crystal
structure of the FabXol3/IgE-Fc complex demonstrates that
omalizumab’s mechanism of inhibition is principally allosteric.
SPR experiments to investigate the mechanism of the inhibi-
tion of IgE-Fc binding to FcRI by FabXol3 revealed a reduc-
tion in the number of available sites for FabXol3 on IgE-Fc
(reducedBmax) when in complexwith FcRI. The inhibition of
IgE binding to FcRI by omalizumab has frequently been inter-
preted in terms of direct competition for overlapping sites, but
there have been reports that indicate that omalizumab can bind
to receptor-bound IgE (22). Here, we have demonstrated
directly the ability of FabXol3 to bind to IgE-Fc when it is
already bound to FcRI to form a trimolecular complex. The
effect of the pre-binding of IgE-Fc to FcRI is to reduce the
number of FabXol3-binding sites on IgE-Fc to less than 10% of
those available in free IgE-Fc; this effect can only be due to
allosteric modulation.
The nature of the interaction of FabXol3 with the IgE-Fc/
FcRI complex provides insights into the mechanism of accel-
erated dissociation of IgE from FcRI. This phenomenon was
first reported for a DARPin and subsequently for omalizumab
(21, 22), the latter at substantially greater concentrations than
those used therapeutically (23), and it is now shown here for
omalizumab Fab fragments. We further conclude that the dis-
sociation occurs only after binding of the second (lower affinity)
FabXol3 molecule. Stated another way, a tetramolecular com-
plex, (FabXol3)2/IgE-Fc/FcRI, must be formed for significant
accelerated dissociation to occur.
Based on our observations with FabXol3, IgE-Fc, and
sFcRI, we envisage the following mechanism occurring for
omalizumab, IgE, and FcRI. IgE binds to FcRI, and under
these conditions a small population of the bound IgEmolecules
adopt a conformation to which omalizumab molecules can
bind. When a second omalizumab molecule binds to form the
tetrameric complex, the energy landscape of IgE is changed
such that the interaction with FcRI is destabilized and a rapid
dissociation of IgE from FcRI occurs.
Figure 9. Analysis of competitionbinding experiments andaccelerateddissociation.A, TR-FRET competition binding experiments between FabXol3 and
-fusion protein for IgE-Fc. Binding between terbium-labeled -fusion protein and Alexa Fluor 647-labeled IgE-Fc was measured with increasing concen-
trations of unlabeled FabXol3 as inhibitor: 0 M (black), 2.5 nM (blue), 5 nM (green), 10 nM (magenta), 20 nM (red). As an inhibitor, FabXol3 affects both the
apparent KD and Bmax values of the interaction between IgE-Fc and -fusion protein, indicating some allosteric inhibition properties. B, comparison of the
ability of FabXol3 to bind to IgE-Fc captured by a C-terminal His tag (red) and IgE-Fc captured by binding to sFcRI (blue); a 2-fold dilution serieswas tested for
each, starting at 1000 nM. The inset shows that FabXol3 can still bind to the IgE-Fc/sFcRI complex, butwith a low Bmax value.C, accelerated dissociation of the
IgE-Fc/sFcRI complex mediated by increasing concentrations of FabXol3. The 1:1 IgE-Fc/sFcRI complex was first established by capturing IgE-Fc on
immobilized sFcRI and then binding FabXol3 in a 5-fold dilution series starting at 5000 nM. The inset shows a magnification of the accelerated dissociation
process. D, comparison of the accelerated dissociation of the IgE-Fc/sFcRI complex mediated by intact omalizumab (black), FabXol (red), or FabXol3 (blue),
each at a concentrationof 5M. All binding experimentswereperformedat 25 °C, except those characterizing the secondFabXol3-binding site (B), whichwere
performed at 5 °C to minimize allosteric communication between the two sites.
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The inhibitory activities of omalizumab thus take advantage
of the intrinsic flexibility of IgE and, for the process of acceler-
ated dissociation, the dynamics of the IgE/FcRI complex. IgE
has a number of unusual structural characteristics compared
with other antibody isotypes, including the presence of the C2
domains and the uniquely conformationally dynamic molten
globule-like character of the C3 domains (33). Together, these
properties create an allosteric communication pathway that
prevents simultaneous engagement of CD23 and FcRI; this is
essential to avoid allergen-independent mast cell activation by
cross-linking of FcRI-bound IgE by the trimeric CD23 mole-
cule (12). Other functional advantages associated with the
dynamicsof IgEhavebeenproposed for themembrane-bound IgE
B cell receptor (16). We have shown here that omalizumab does
not utilize the expected orthosteric mechanism for inhibition of
the IgE/FcRI interaction, but rather it exploits these unusual
dynamic properties of IgE. Furthermore, omalizumab can actively
dissociate IgE from FcRI, albeit at concentrations higher than
used therapeutically, by employing allostery and the intrinsic flex-
ibility of IgE that persists evenwhen in complexwith its receptors.
Experimental procedures
Cloning, protein expression, and purification
Omalizumab human IgG1 Fab, FabXol3, and His-tagged
IgE-Fc were cloned, expressed, and purified using methods
described in Drinkwater et al. (16). IgE-Fc was produced as
described previously (34). Omalizumab was purchased from
Novartis EuropharmLtd. The 2:1 FabXol3/IgE-Fc complexwas
purified by size-exclusion chromatography, eluted into 25 mM
Tris-HCl, pH 7.5, 20 mM NaCl, and 0.05 (w/v) NaN3, and con-
centrated to 23 mg/ml.
Surface plasmon resonance
SPR experiments were carried out on a Biacore T200 instru-
ment (GE Healthcare). Specific surfaces were prepared either
by covalently coupling proteins using the amine coupling pro-
tocol (GEHealthcare), with coupling densities	300 resonance
units, or capturingHis-tagged proteins using an anti-His sensor
surface. For capturing His-tagged ligands, an anti-His tag
monoclonal antibody was employed and immobilized accord-
ing to themanufacturer’s instructions (BiacoreHisCaptureKit,
GE Healthcare). In binding experiments, association times of
180–240 s were typically used, and dissociation components
were monitored for at least 500 s. Injections were performed at
a flow rate of 25 l min1 in a running buffer of 20 mMHEPES,
pH 7.4, 150 mM NaCl, and 0.005% (v/v) surfactant P-20 (GE
Healthcare). Most experimental binding measurements were
performed at 25 °C; some binding experiments were performed
over a range of temperatures (5–35 °C) to control the degree of
accelerated dissociation in the system; low temperatures mini-
mize this phenomenon, and higher temperatures increase it. In
all cases, standard double referencing data subtractionmethods
were used (35), and kinetic fits were performed using Origin
software (OriginLab).
TR-FRET
IgE-Fc was labeled with donor fluorophore by reacting 4
mg/ml protein in 100mM sodiumbicarbonate, 50mMNaCl, pH
9.3, with a 5-fold molar excess of terbium chelate isothiocya-
nate (Invitrogen). After a 3-h incubation at room temperature
with agitation, excess unreacted fluorophore was removed by
dialyzing into PBS (20 mM phosphate buffer saline, 150 mM
NaCl, pH 7.4). sFcRI-IgG4-Fc fusion protein (-) (36) was
labeled with acceptor fluorophore by reacting 3 mg/ml protein
with a 2.5-fold molar excess of Alexa Fluor 647 succinimidyl
ester (Invitrogen) for 1 h at room temperature. Excess fluoro-
phore was removed by dialyzing into PBS.
TR-FRET inhibition assays were performed by competing 1
nM terbium-labeled IgE-Fc and 0–20 nM Alexa Fluor 647-
labeled sFcRI-IgG4-Fc with a range of concentrations of
FabXol3. Assays were conducted in 384-well hi-base white
plates (Greiner BioOne) using Lanthascreen buffer (Invitrogen)
as a diluent. The plate was left to incubate overnight at room
temperature and read by an Artemis plate reader (Berthold
Technologies). TR-FRET ratios were then calculated for each
well as the emission of acceptor at 665 nm divided by the emis-
sion of donor at 620 nm multiplied by 10,000.
Intramolecular FRET
Measurements of intramolecular FRET were performed
essentially as described in Drinkwater et al. (16), using an
IgE-Fc mutant (E289C) biotinylated at the C terminus using a
BirA tag (Avidity). This protein was then fluorescently labeled
using a thiol-reactive terbium chelate (Invitrogen) and bound
to a monovalent, amine-reactive Alexa Fluor 488 (Invitrogen)-
labeled streptavidin (37). The anti-IgE Fabs at various concen-
trations were added to IgE-Fc in PBS, to give a final concentra-
tion of 25 nM IgE-Fc, and incubated for 120 min at 25 °C. FRET
wasmeasured on anAnalyst HTmicroplate reader (LJL Biosys-
tems) with an excitation wavelength of 330 nm and emission
wavelengths of 485 and 520 nm. Each sample was measured in
quadruplicate, and in at least two separate experiments.
Crystallization
Crystals up to 400min lengthwere grown at 18 °Cusing the
sitting drop vapor diffusion method. The reservoir contained
50l of 4% (w/v) PEG 8000 and 0.03 M sodium fluoride, and the
drop contained 100 nl of protein solution and 300 nl of reservoir.
Despite extensive efforts at optimization, the diffraction quality of
the crystals could not be further improved beyond that used
for this study. Crystals typically started to grow after a few
days and often dissolved in their drops, but they could be
stabilized in 4 M trimethylamine N-oxide, which was suc-
cessfully used as a cryoprotectant.
X-ray data collection and processing
Data were collected at beamlines I02 and I03 at the Diamond
Light Source (Harwell, UK). Integration was performed using
XDS (38) as implemented in the xia2 package (39). The crystals
diffracted anisotropically, and data frommultiple crystals were
merged. The data were scaled to 3.7 Å resolution with AIM-
LESS from the CCP4 suite (40, 41) and then truncated to reso-
lution limits of 3.7 Å (a*), 3.9 Å (b*), and 4.2 Å (c*) using the
UCLA Diffraction Anisotropy Server (42). Calculation of the
Matthews coefficient indicated a solvent content of62%, for a
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single 2:1 FabXol3/IgE-Fc complex (molecular mass of 170
kDa) in the asymmetric unit.
Structure determination, model building, and refinement
The structure was solved by molecular replacement with
PHASER (43) and MOLREP (44) from the CCP4 suite (40)
using protein atoms from PDB entry 2WQR (8) and a 1.9 Å
resolution omalizumab Fab structure, belonging to the same
space group as published crystal structures (19, 24) as search
models. Refinementwas initially performedwithREFMAC (45)
and later with PHENIX (46) and alternated with manual model
building in Coot (47). The quality of the model was assessed
withMolProbity (48) and POLYGON (49). Data processing and
refinement statistics are presented in Table 1. A region of the
electron density map is shown in supplemental Fig. S4. Inter-
faces were analyzed with PISA (50), figures were prepared with
PyMOL (51), and movies were prepared with Chimera (52),
PyMOL (51), and the eMovie plugin (53) for PyMOL.
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